General Information of Drug Transporter (DT)
DT ID	DTD0029 Transporter Info
Gene Name	SLCO1A2
Protein Name	Organic anion transporting polypeptide 1A2
Gene ID	6579
UniProt ID	P46721
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs3764043
Site of GPD	chr12:21335070 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0877/439 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the decreased drug clearance in patients (compare with Genotypes CT + TT)		[ 1]
Imatinib	N.A.	Muscular Diseases	Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.		[ 1]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype CC.		[ 2]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.		[ 1]
Genetic Polymorphism	rs3834939
Site of GPD	chr12:21334836-21334838 (GRCh38.p12)
GPD Type	Indel Insertion and Deletion
Allele(s) in dbSNP	dupT
Minor Allele Frequency	T=0.3708/1857 (Global)
Genotypes T/del + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Rocuronium	Drug Info	Healthy Individuals	Correlated with the decreased drug clearance in healthy individuals (compare with genotype del/del)		[ 2]
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotypes T/del + TT are associated with decreased clearance of rocuronium in healthy individuals as compared to genotype del/del.		[ 2]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the TT genotype may have decreased clearance of rocuronium as compared to patients with the del/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.		[ 2]
Genotype del/T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the T/del genotype may have decreased clearance of rocuronium as compared to patients with the del/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.		[ 2]
Genotype del/del	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the del/del genotype may have increased clearance of rocuronium as compared to patients with the del/T and TT genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.		[ 2]
Genetic Polymorphism	rs7967354
Site of GPD	chr12:21271069 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.6870/1359 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with decreased dose of rocuronium in women as compared to genotypes CT + TT.		[ 3]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the rs7967354 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.		[ 3]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the rs7967354 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.		[ 3]
Genetic Polymorphism	rs4148978
Site of GPD	chr12:21335741 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6370/1260 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 4]
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype CC.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Muscular Diseases	Genotype CC is associated with increased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.		[ 1]
Genetic Polymorphism	rs10841795
Site of GPD	chr12:21334610 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.9480/1876 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Raltegravir	N.A.	Leukemia, Myeloid, Acute	Allele A is not associated with concentration of raltegravir in people with HIV Infections as compared to allele G.		[ 5]
Ceftriaxone	N.A.	Dizziness	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.		[ 6]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tamoxifen	N.A.	Dizziness	Genotypes AG + GG is associated with decreased severity of Dizziness when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.		[ 7]
Genetic Polymorphism	rs11568563
Site of GPD	chr12:21304500 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>G
Minor Allele Frequency	T=0.9740/1927 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Raltegravir	N.A.	Leukemia, Myeloid, Acute	Allele G is not associated with concentration of raltegravir in people with HIV Infections as compared to allele T.		[ 5]
Celiprolol	N.A.	Dizziness	Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele T.		[ 9]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotypes GT + TT are not associated with clearance of rocuronium in healthy individuals as compared to genotype GG.		[ 2]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele T is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele G.		[ 9]
Genetic Polymorphism	rs750165758
Site of GPD	chr12:21304457 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rocuronium	N.A.	Leukemia, Myeloid, Acute	Genotypes CC + CT are not associated with clearance of rocuronium in healthy individuals as compared to genotype TT.		[ 2]
Genetic Polymorphism	rs4149009
Site of GPD	chr12:21267537 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6150/1217 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Dizziness	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 10]
Methotrexate	N.A.	Dizziness	Allele T is not associated with dose of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 11]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 10]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Dizziness	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 11]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CC genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 TT genotype may have increased clearance of methotrexate as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance		[ 11]
Genetic Polymorphism	rs45502302
Site of GPD	chr12:21306920 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele T is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.		[ 9]
Genetic Polymorphism	rs4149000
Site of GPD	chr12:21295063 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9260/1832 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Muscular Diseases	Allele T is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele C.		[ 12]
Genetic Polymorphism	rs4148977
Site of GPD	chr12:21335814 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.6370/1260 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Muscular Diseases	Genotype CC is associated with increased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.		[ 1]
References
1	Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther. 2011 Jul;90(1):157-63.
2	The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries. Eur J Clin Pharmacol. 2017 Aug;73(8):957-963.
3	First genome-wide association study on rocuronium dose requirements shows association with SLCO1A2. Br J Anaesth. 2021 May;126(5):949-957.
4	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. Drug Metab Pharmacokinet. 2022 Apr;43:100441.
5	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother. 2014 Jan;69(1):241-5.
6	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Dec;58(12):1550-1556.
7	Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenet Genomics. 2023 Jan 01;33(1):10-18.
8	Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clin Transl Sci. 2022 Feb;15(2):409-421.
9	Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One. 2013 Sep 25;8(9):e75359.
10	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
11	Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia. Leuk Res. 2018 Feb;65:61-66.
12	Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther. 2019 Dec;106(6):1353-1361.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.